FBXL19

Across TCGA pan-cancer cohorts, FBXL19 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FBXL19 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FBXL19 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FBXL19 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

HNSC, LUAD, and GBM are the cancer types where FBXL19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.443	0.931	.014	10	view →
LUAD	DFS	Tertile	II,III,IV	1.000	0.518	.040	6	view →
GBM	DFS	Median	All	0.492	0.298	.020	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FBXL19–HNSC (DFS)

Open the HNSC breakdown →